Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.
Diala Alhaj MoustafaZainab ImranRoua IsmailMenatallah RayanAlain-Pierre GadeauHussein EldassoukiNabeel AbdulrahmanFatima MraichePublished in: Molecular biology reports (2022)
Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings.
Keyphrases
- sars cov
- coronavirus disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- respiratory syndrome coronavirus
- peritoneal dialysis
- angiotensin converting enzyme
- type diabetes
- glycemic control
- single cell
- cell therapy
- stem cells
- patient reported outcomes
- intensive care unit
- metabolic syndrome
- insulin resistance
- mesenchymal stem cells
- skeletal muscle
- combination therapy
- replacement therapy
- patient reported